Oncology Speed Read Publication Snapshot

Exploring RAS-targeted approaches beyond G12C in non-small cell lung cancer (NSCLC)

Putting recent daraxonrasib publication data into context

Prof. David Hong

Prof. Michael Duruisseaux

Dr Hidehito Horinouchi

Publication Date

Sep 2026

Summary and next episodes

Downloadable resources

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

Professor David Hong meets with Professor Michael Duruisseaux and Dr Hidehito Horinouchi to discuss the evolving landscape of RAS-mutant NSCLC, including the recent publication of clinical data for daraxonrasib in The New England Journal of Medicine.

The experts will explore the diversity of RAS alterations in NSCLC, the unmet need beyond KRAS G12C, and the emergence of broader RAS-targeted approaches, including pan-RAS inhibitors. They will discuss how the findings from the daraxonrasib study contribute to the broader understanding of targeting RAS-mutant disease.

Drawing on perspectives from the US, Europe, and Japan, the experts will consider how these recent clinical data fit within the changing treatment landscape, including the potential role of broader RAS inhibition for patients with non-G12C alterations, and what ongoing clinical trials may mean for future treatment strategies and clinical practice.

This video offers expert perspectives on an evolving area of NSCLC following the recent New England Journal of Medicine publication of daraxonrasib data.

To find out more about the publication, navigate to the tab above to view or download the Publication snapshot for the key points.

Clinical takeaways

RAS-mutant NSCLC is heterogeneous: comprehensive biomarker testing is important
Non-G12C RAS-mutant NSCLC remains a major unmet need given limited targeted treatment options
Daraxonrasib provides a pan-RAS approach, with Phase 1/2 data supporting further evaluation at 200 mg once daily in RASolve 301

Understand the latest clinical data and the evolving profiles of novel KRAS-directed therapies
Know the potential placement of novel KRAS-directed therapies in the future treatment landscape

Dr David S. Hong is a Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program), Clinical Medical Director of the Clinical Translational Research Center (CTRC), and Associate Vice President of Clinical Research at The University of Texas MD Anderson Cancer Center.

Dr Hong was instrumental in forming one of the largest and most innovative Phase 1 clinical trial units in the world, with over 1300 patients enrolled in clinical trials in FY2021 and over 400 active ongoing clinical trials.

Dr Hong has been the Principal Investigator of over 120 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. He has published over 374 publications in Peer-reviewed Journals such as NEJM, Lancet Oncology, JCO and Nature.

He has been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib, larotrectinib, tesotumab vendotin, and sotorasib the first drug to target KRAS that have led to FDA approval.

He has also helped found 2 companies OncoResponse and Telperian.

He is an expert on c-Met, NTRK, KRAS, and adoptive cellular therapy in solid tumors and has led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial. He been awarded the ASCO Young Investigator Award, the Jesse Jones award, Best Boss award at MD Anderson, Irwin Krakoff Award for Clinical Research, and the Gerald P. Bodey award for education and Mentor of the year award in the Division of Cancer Medicine, MD Anderson.

Prof. David Hong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astra-Zeneca, Bayer, Bristol- Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai, Endeavor, Erasca, F. Hoffmann- LaRoche, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, TCR2, Teckro, Turning Point Therapeutics and VM Oncology.

Michael Duruisseaux is Professor in Medecine at the University of Lyon in France and Thoracic Oncologist at Hospices Civils de Lyon, the second largest French university hospital.

He is the head of a thoracic oncology unit and of an early phase study unit dedicated to lung cancer patients.

He is the PI of the TheraLung Lab at Cancer Research Center of Lyon (INSERM 1052 CNRS 5286) that aims to discover therapeutic vulnerabilities in oncogene-addicted lung cancers.

His field of expertise is clinical and translational research in oncogene-addicted lung cancer, including the development of new treatment approaches.

He is the lead author or the co-author of more than 100 peer-reviewed scientific articles.

Prof. Michael Duruisseaux has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Pfizer, Boehringer Ingelheim, AstraZeneca, Roche, BMS, AbbVie, Takeda, MSD, Guardant, Novartis, Amgen, GSK, Sanofi, Revolution Medicines, Johnson and Johnson

Dr Hidehito Horinouchi is a Medical Oncologist and Assistant Chief at the National Cancer Center Hospital, Tokyo, Japan.

His research primarily focuses on multimodal treatment strategies for thoracic malignancies such as chemotherapy, targeted agents, immunotherapy, surgery, and radiotherapy.

Dr Hidehito Horinouchi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, AstraZeneca, BMS, Chugai/Roche, Daiichi-Sankyo, Kyowa-Kirin, MSD, Natera, Ono, and Taiho

Download Publication Snapshot - PDF